News
SGHT
4.270
+5.96%
0.240
Sight Sciences Is Maintained at Neutral by Piper Sandler
Dow Jones · 1d ago
Sight Sciences Price Target Raised to $4.00/Share From $3.50 by Piper Sandler
Dow Jones · 1d ago
Piper Sandler Maintains Neutral on Sight Sciences, Raises Price Target to $4
Benzinga · 1d ago
Piper Sandler Reaffirms Their Hold Rating on Sight Sciences (SGHT)
TipRanks · 2d ago
Sight Sciences price target raised to $4 from $3.50 at Piper Sandler
TipRanks · 2d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sight Sciences (SGHT) and Cullinan Management (CGEM)
TipRanks · 3d ago
Sight Sciences: Hold Rating Amid Promising TearCare Potential and Market Access Challenges
TipRanks · 3d ago
Weekly Report: what happened at SGHT last week (0609-0613)?
Weekly Report · 4d ago
Weekly Report: what happened at SGHT last week (0602-0606)?
Weekly Report · 06/09 09:09
Sight Sciences Holds Annual Stockholders Meeting
TipRanks · 06/05 21:24
Weekly Report: what happened at SGHT last week (0526-0530)?
Weekly Report · 06/02 09:10
Sight Sciences Independent Chairman Acquires 7.8% More Stock
Simply Wall St · 06/01 12:28
Friday 5/30 Insider Buying Report: BLDR, SGHT
NASDAQ · 05/30 18:27
Weekly Report: what happened at SGHT last week (0519-0523)?
Weekly Report · 05/26 09:10
Sight Sciences Is Maintained at Neutral by Citigroup
Dow Jones · 05/22 17:48
Sight Sciences Price Target Raised to $3.60/Share From $3.20 by Citigroup
Dow Jones · 05/22 17:48
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $3.6
Benzinga · 05/22 17:38
Sight Sciences price target raised to $3.60 from $3.20 at Citi
TipRanks · 05/22 10:40
Weekly Report: what happened at SGHT last week (0512-0516)?
Weekly Report · 05/19 09:09
Sight Sciences, Inc. (NASDAQ:SGHT) Surges 44% Yet Its Low P/S Is No Reason For Excitement
Simply Wall St · 05/14 13:57
More
Webull provides a variety of real-time SGHT stock news. You can receive the latest news about Sight Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.